ATE283053T1 - Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure - Google Patents

Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure

Info

Publication number
ATE283053T1
ATE283053T1 AT00967673T AT00967673T ATE283053T1 AT E283053 T1 ATE283053 T1 AT E283053T1 AT 00967673 T AT00967673 T AT 00967673T AT 00967673 T AT00967673 T AT 00967673T AT E283053 T1 ATE283053 T1 AT E283053T1
Authority
AT
Austria
Prior art keywords
estramustine phosphate
amino acid
medicinal compositions
parenteral application
application containing
Prior art date
Application number
AT00967673T
Other languages
English (en)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of ATE283053T1 publication Critical patent/ATE283053T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00967673T 1999-09-16 2000-09-13 Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure ATE283053T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921960.2A GB9921960D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and amino acids
PCT/EP2000/008983 WO2001019372A1 (en) 1999-09-16 2000-09-13 Formulations for parenteral use of estramustine phosphate and amino acids

Publications (1)

Publication Number Publication Date
ATE283053T1 true ATE283053T1 (de) 2004-12-15

Family

ID=10861070

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967673T ATE283053T1 (de) 1999-09-16 2000-09-13 Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure

Country Status (22)

Country Link
EP (1) EP1214078B1 (de)
JP (1) JP2003509372A (de)
KR (1) KR20020059592A (de)
CN (1) CN1373667A (de)
AT (1) ATE283053T1 (de)
AU (1) AU779922B2 (de)
BR (1) BR0014071A (de)
CA (1) CA2384726A1 (de)
CZ (1) CZ2002945A3 (de)
DE (1) DE60016252D1 (de)
EA (1) EA005311B1 (de)
GB (1) GB9921960D0 (de)
HK (1) HK1048948A1 (de)
HU (1) HUP0202729A3 (de)
IL (1) IL148513A0 (de)
MX (1) MXPA02002854A (de)
NO (1) NO20021302L (de)
NZ (1) NZ518182A (de)
PL (1) PL354746A1 (de)
SK (1) SK3442002A3 (de)
WO (1) WO2001019372A1 (de)
ZA (1) ZA200202689B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
EP2531047B1 (de) 2010-02-05 2024-11-13 Phosphagenics Limited Träger mit einem nichtneutralisierten tocopherylphosphat
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
EP3265063A4 (de) 2015-03-03 2018-11-07 Cureport, Inc. Doppelt beladene liposomale pharmazeutische formulierungen
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
WO2024102547A1 (en) * 2022-11-11 2024-05-16 Michael Farber Anhydrous compositions of polysorbates and cyclodextrins for shelf stable drug combinations with macrocyclic lactone complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度tcf製剤
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Also Published As

Publication number Publication date
NO20021302D0 (no) 2002-03-15
JP2003509372A (ja) 2003-03-11
AU779922B2 (en) 2005-02-17
HUP0202729A2 (hu) 2003-01-28
KR20020059592A (ko) 2002-07-13
HK1048948A1 (zh) 2003-04-25
MXPA02002854A (es) 2003-07-21
EP1214078A1 (de) 2002-06-19
DE60016252D1 (de) 2004-12-30
EA200200368A1 (ru) 2002-10-31
BR0014071A (pt) 2002-05-21
CN1373667A (zh) 2002-10-09
AU7776200A (en) 2001-04-17
NO20021302L (no) 2002-04-24
HUP0202729A3 (en) 2003-12-29
GB9921960D0 (en) 1999-11-17
PL354746A1 (en) 2004-02-23
SK3442002A3 (en) 2002-09-10
WO2001019372A1 (en) 2001-03-22
EA005311B1 (ru) 2004-12-30
IL148513A0 (en) 2002-09-12
EP1214078B1 (de) 2004-11-24
CZ2002945A3 (cs) 2002-07-17
ZA200202689B (en) 2003-10-29
CA2384726A1 (en) 2001-03-22
NZ518182A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
ATE283053T1 (de) Parenteral anzuwendende arzneizusammensetzungen enthaltend estramustinphosphat und aminosäure
TR200002299T2 (tr) Epotilon kompozisyonları.
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
PL347671A1 (en) Compounds and compositions for delivering active agents
IL153297A0 (en) Compounds and compositions for delivering active agents
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
AU2274201A (en) Compounds and compositions for delivering active agents
TNSN05180A1 (en) Liquid pharmaceutical formulations of palonosetron
CA2338358A1 (en) Compounds and compositions for delivering active agents
EP0993831A3 (de) Komponente und Zusammensetzungen zur Verabreichung von Wirkstoffen
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
ATE378070T1 (de) Zusammensetzung mit fulvestrant
EA200200234A1 (ru) Препараты для парентерального применения эстрамустин фосфата и альбумина
BR0014062A (pt) Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas
IT1298442B1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
BR9914031A (pt) Composições farmacêuticas micronizadas
BR0014063A (pt) Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties